Abstract
5-Pyrimidinyl-2-aminothiazole 1 was identified as an inhibitor of cyclin-dependent kinases (CDKs) by a screening of the Merck sample repository. The introduction of a methyl group at the C-5 or C-6 position on the pyrimidine ring, directed toward the gate keeper residue of CDK4 (Phe93), led to significant enhancement of selectivity for CDK4 over other CDKs. Compound 3 exhibited more than 300-fold selectivity for CDK4 over CDK1, 2, 5, 7, and 9. Subsequent improvements in aqueous solubility afforded compound 4, which is available for further in vivo studies and this compound inhibited pRb phosphorylation and BrdU incorporation in tumor models.
MeSH terms
-
Bromodeoxyuridine / antagonists & inhibitors
-
Bromodeoxyuridine / metabolism
-
CDC2 Protein Kinase / antagonists & inhibitors
-
Cyclin-Dependent Kinase 2 / antagonists & inhibitors
-
Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
-
Cyclin-Dependent Kinase 5 / antagonists & inhibitors
-
Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
-
Cyclin-Dependent Kinase 9 / antagonists & inhibitors
-
Cyclin-Dependent Kinase-Activating Kinase
-
Cyclin-Dependent Kinases / antagonists & inhibitors*
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Phosphorylation
-
Pyrimidines / pharmacology*
-
Retinoblastoma Protein / antagonists & inhibitors
-
Retinoblastoma Protein / metabolism
-
Thiazoles / pharmacology*
-
Tumor Cells, Cultured
Substances
-
Enzyme Inhibitors
-
Pyrimidines
-
Retinoblastoma Protein
-
Thiazoles
-
Cyclin-Dependent Kinase 5
-
CDC2 Protein Kinase
-
Cyclin-Dependent Kinase 2
-
Cyclin-Dependent Kinase 4
-
Cyclin-Dependent Kinase 6
-
Cyclin-Dependent Kinase 9
-
Cyclin-Dependent Kinases
-
Bromodeoxyuridine
-
Cyclin-Dependent Kinase-Activating Kinase